FilingSEC EDGAR6-K
Radiopharm Theranostics Announces Positive Phase 1 Data for RAD301
· SEC accepted
StagePhase 1
Filing content
Radiopharm Theranostics reported positive Phase 1 imaging trial data for RAD301 in pancreatic cancer patients, demonstrating safety and tumor uptake.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…